[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Yuhan Corporation\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":264},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,54,82,107,132,166,192,217,239],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":53},"100591052","phase-1-clinical-trial-of-yh32364-in-patients-with-locally-advanced-or-metastatic-egfr-overexpressing-solid-tumors-100591052",false,"NCT06975410","Clinical Trial of YH32364 in Patients With Locally Advanced or Metastatic EGFR Overexpressing Solid Tumors","A Phase 1\u002F2, Open-label, Multicenter, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of YH32364 in Patients With Locally Advanced or Metastatic Solid Tumors","Inclusion Criteria:\n\n* Must sign an informed consent form (ICF) prior to any study specific procedures\n* ECOG performance status 0 or 1\n* Estimated life expectancy of at least 3 months\n* A woman must not be breastfeeding\n* Have at least one measurable lesion, not previously irradiated and not chosen for biopsy during the study screening period, that can be accurately measured at baseline ≥10 mm in the longest diameter (except lymph nodes which must have a short axis of ≥15 mm) with computerized tomography (CT) or magnetic resonance imaging (MRI), are suitable for accurate repeated measurements.\n\n\\[Dose Escalation Only\\] Locally advanced or metastatic EGFR overexpressing solid tumor\\* that is refractory or intolerable on all available standard therapy and that is considered uncurable by local therapy\n\n\\* One of the following pathologically confirmed EGFR overexpressing (IHC3+ or IHC2+) tumors.\n\n* Head and neck squamous cell carcinoma (HNSCC)\n* Non-small cell lung cancer (NSCLC): squamous cell carcinoma (SqCC)\n* Esophageal squamous cell carcinoma (ESCC)\n* Biliary tract cancer (BTC)\n* Uterine cervical cancer\n* Vulvar cancer\n* Urothelial cancer\n* Squamous cell carcinoma of other origin of tumor (e.g., skin squamous cell tumor)\n\n\\[Dose Expansion Only\\] Cohort 1: Pathologically confirmed EGFR overexpressing (IHC3+ or IHC2+), locally advanced or metastatic HNSCC other than nasopharyngeal carcinoma (NPC)\\* that is refractory or intolerable on all available standard therapy and that is considered uncurable by local therapy.\n\nExclusion Criteria:\n\n* Known uncontrolled central nervous system (CNS) metastases, spinal cord compression, and\u002For carcinomatous meningitis\n* Have history of a second primary cancer with the exception of\n\n  * curatively treated non-melanomatous skin cancer\n  * curatively treated cervical or breast carcinoma in situ, or\n  * other malignancy with no known active disease present and no treatment administered during the last 2 years\n* Have history of or current Class II, III or IV heart failure as defined by the New York Heart Association (NYHA)\n* Have history of acute coronary syndromes, including myocardial infarction, coronary artery bypass graft, unstable angina, coronary angioplasty or stenting within past 24 weeks\n* Have history of (non-infectious) interstitial lung disease (ILD) or pneumonitis that required steroids, or any evidence of current ILD or pneumonitis\n* Have autoimmune disease that has required systemic treatment\n* Infection with human immunodeficiency virus (HIV)\n* Active chronic hepatitis B or chronic hepatitis C\n\n\\[Prior\u002FConcomitant Therapy\\]\n\n* Have received systemic steroid therapy\n* Previous treatment with a 4-1BB\u002FCD137-modulating agent\n* Have used a live vaccine within 4 weeks\n* Have received treatment with immunotherapy, biological therapies, targeted small molecules, or hormonal therapies\n* Have received radiation therapy\n* Have received cytotoxic chemotherapy","ALL","18 Years",{"count":19,"type":20},80,"ESTIMATED","INTERVENTIONAL",[23,24],"PHASE1","PHASE2","This is a study for people with locally advanced or metastatic cancer for whom previous treatment was not successful. Adults aged 18 and over with advanced cancer with Epidermal Growth Factor Receptor (EGFR) overexpressing can join the study. The purpose of this study is to find out whether a medicine called YH32364 helps people with locally advanced or metastatic cancers with EGFR overexpression.",[27,28,29],"EGFR Overexpression","Locally Advanced Solid Tumor","Metastatic Solid Tumor",[31,32,33,34,35,36,37,38,39,40],"YH32364","EGFR\u002F4-1BB bispecific antibody","Solid tumor","Head and neck squamous cell carcinoma (HNSCC)","Non-small cell lung cancer (NSCLC)","Esophageal squamous cell carcinoma (ESCC)","Biliary tract cancer (BTC)","Uterine cervical cancer","Vulvar cancer","Urothelial cancer","RECRUITING","2026-06-09",{"date":44,"type":45},"2026-06-10","ACTUAL",{"date":47,"type":45},"2025-06-12",{"date":49,"type":20},"2029-12",{"name":51,"class":52},"Yuhan Corporation","INDUSTRY",4,{"id":55,"slug":56,"hasResults":11,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":4,"eligibilityCriteria":60,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":61,"targetDuration":4,"studyType":21,"phases":63,"briefSummary":64,"conditions":65,"keywords":67,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":81},"100479512","phase-1-clinical-trial-of-yh32367-in-patients-with-her2-positive-locally-advanced-or-metastatic-solid-tumor-100479512","NCT05523947","Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor","A Phase 1\u002F2, Open-label, Multicenter, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of YH32367 in Patients With HER2-Positive Locally Advanced or Metastatic Solid Tumors","Inclusion Criteria:\n\n\\[Dose Escalation Part\\]\n\n* Pathologically confirmed HER2-positive\n* Mandatory provision of tumor tissue sample\n\n\\[Dose Expansion Part\\]\n\n* Patients who have at least one measurable lesion\n* Mandatory provision of tumor tissue sample\n\n  1. Cohort 1: Pathologically confirmed HER2-positive biliary tract cancer\n  2. Cohort 2: Pathologically confirmed HER2-positive metastatic solid tumor malignancy other than breast and gastric or gastroesophageal junction adenocarcinoma and biliary tract cancer\n\nExclusion Criteria:\n\n* Uncontrolled central nervous system (CNS) metastases\n* Spinal cord compression\n* Carcinomatous meningitis\n* Acute coronary syndromes\n* Heart failure\n* Interstitial lung disease (ILD)\n* Pneumonitis\n* History of a second primary cancer\n* Human immunodeficiency virus (HIV)\n* Active chronic hepatitis B\n* Hepatitis C\n* Systemic steroid therapy\n* Autoimmune disease",{"count":62,"type":20},147,[23,24],"This first-in-human study will be counducted to evaluate the safety, tolerability, pharmacokinetics (PK) and anti-tumor activity of YH32367 in Patients with HER2-Positive Locally Advanced or Metastatic Solid Tumors.",[66],"HER2-Positive Solid Tumor",[68,69,33,70,71,72,73],"YH32367","HER2\u002F4-1BB bispecific antibody","Breast cancer","Gastric cancer","HER2-positive","Biliary tract cancer",{"date":75,"type":45},"2026-06-11",{"date":77,"type":45},"2022-08-26",{"date":79,"type":20},"2028-04-30",{"name":51,"class":52},19,{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":4,"eligibilityCriteria":88,"healthyVolunteers":89,"sex":16,"minAge":90,"maxAge":91,"enrollmentInfo":92,"targetDuration":4,"studyType":21,"phases":94,"briefSummary":95,"conditions":96,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":106},"100629090","phase-1-bioequivalence-be-study-between-yhp2511-and-yhp2511a-in-healthy-volunteers-100629090","NCT07470125","Bioequivalence (BE) Study Between YHP2511 and YHP2511A in Healthy Volunteers","An Open-label, Randomized, Fasting, Single-dose, 2-sequence, 2-period, Crossover Study to Evaluate the Bioequivalence of YHP2511 With YHP2511A in Healthy Adult Volunteers","Inclusion Criteria:\n\n* Adults aged 19 to 55 years at the time of screening visit.\n* Those whose weight is ≥ 50 kg (≥ 45 kg for females) and their body mass index (BMI) shall be between 18.0 kg\u002Fm2 and 30.0 kg\u002Fm2\n* Those without clinically significant congenital or chronic diseases at the screening visit and without any pathological symptom or opinion after an internal medicine examination\n* Those who express their voluntary consent to participate in the trial by signing a written consent\n\nExclusion Criteria:\n\n* Those who have participated in a bioequivalence study or other clinical trials and have been administered with investigational products in 6 months prior to the first administration.\n* Others who are judged ineligible to participate in the trial by the principal investigator\n* Female volunteers who are pregnant, suspected to be pregnant or breastfeeding.",true,"19 Years","55 Years",{"count":93,"type":20},60,[23],"A randomized, open-label, single-dose, 2-sequence, 2-period, crossover clinical trial to investigate the bioequivalence between YHP2511 and YHP2511A in healthy volunteers",[97],"Healthy Subjects","2026-05-28",{"date":100,"type":45},"2026-06-02",{"date":102,"type":20},"2026-06-23",{"date":104,"type":20},"2026-07-11",{"name":51,"class":52},1,{"id":108,"slug":109,"hasResults":11,"nctId":110,"briefTitle":111,"officialTitle":112,"acronym":4,"eligibilityCriteria":113,"healthyVolunteers":89,"sex":16,"minAge":90,"maxAge":114,"enrollmentInfo":115,"targetDuration":4,"studyType":21,"phases":117,"briefSummary":118,"conditions":119,"keywords":120,"overallStatus":123,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":4},"100637246","phase-1-bioequivalence-study-between-yhp2508c-and-yhr2603-in-healthy-subjects-100637246","NCT07584304","Bioequivalence Study Between YHP2508C and YHR2603 in Healthy Subjects","An Open-label, Randomized, Fasting, Single-dose, Oral Administration, 2-sequence, 4-period, Replicate Crossover Study to Evaluate Bioequivalence Between YHP2508C and YHR2603 in Healthy Subjects","Inclusion Criteria:\n\n* BMI 18-30 kg\u002Fm2\n* Those without clinically significant congenital or chronic diseases\n\nExclusion Criteria:\n\n* Those who have participated in a bioequivalence study or other clinical trials and have been administered investigational products within 6 months prior to the first administration.\n* Those who are judged ineligible to participate in the trial by the principal investigator.\n* Female volunteers who are pregnant, suspected to be pregnant or breastfeeding.","54 Years",{"count":116,"type":20},44,[23],"An open-label, randomized, fasting, single-dose, oral administration, 2-sequence, 4-period, replicate crossover study to evaluate bioequivalence between YHP2508C and YHR2603 in healthy subjects",[97],[121,122],"Pharmacokinetics","Bioequivalence","NOT_YET_RECRUITING","2026-05-12",{"date":126,"type":45},"2026-05-13",{"date":128,"type":20},"2026-07-10",{"date":130,"type":20},"2026-09-15",{"name":51,"class":52},{"id":133,"slug":134,"hasResults":11,"nctId":135,"briefTitle":136,"officialTitle":137,"acronym":138,"eligibilityCriteria":139,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":140,"enrollmentInfo":141,"targetDuration":4,"studyType":21,"phases":143,"briefSummary":144,"conditions":145,"keywords":148,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":157,"lastUpdatePostDateStruct":158,"startDateStruct":160,"completionDateStruct":162,"leadSponsor":164,"locationsCount":165},"100624893","phase-2-phase-2-study-of-lesigercept-in-adult-patients-with-chronic-spontaneous-urticaria-who-are-inadequately-controlled-by-h1-antihistamines-100624893","NCT07415551","Phase 2 Study of Lesigercept in Adult Patients With Chronic Spontaneous Urticaria Who Are Inadequately Controlled by H1-Antihistamines","A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Efficacy, Safety and Tolerability of Lesigercept in Adult Patients With Chronic Spontaneous Urticaria Who Are Inadequately Controlled by H1-Antihistamines (CLEAR)","CLEAR","Inclusion Criteria:\n\n* Chronic spontaneous urticaria for ≥6 months, uncontrolled on 2nd-generation H1-antihistamines (UAS7≥16, ISS7≥8, HSS7≥8).\n* Stable dose of 2nd-generation H1-antihistamines for ≥7 days; symptom diary compliance ≥80%.\n* Adults 18-75 years; informed consent signed; contraception and pregnancy test requirements for both genders.\n* ≥80% adherence to antihistamines during screening.\n\nExclusion Criteria:\n\n* Any medical or lab findings suggesting risk of worsening co-existing conditions during the study.\n* Clinically significant cardiovascular, neurological, psychiatric, pulmonary, renal, hepatic, endocrine, metabolic, hematologic, gastrointestinal, or immunodeficiency disorders that may compromise safety or study results.\n* History of malignancy within 5 years (except certain cured skin\u002Fcervical cancers) or chronic urticaria with known etiology other than CSU (e.g., inducible urticaria, autoimmune diseases).\n* Active or high-risk parasitic infections, chronic\u002Frecurrent infections (e.g., TB, HBV, HCV, HIV), or hypersensitivity\u002Fanaphylaxis to study drugs or related classes.\n* Skin diseases affecting assessments (e.g., atopic dermatitis, psoriasis) or history of drug\u002Falcohol abuse within 6 months.","75 Years",{"count":142,"type":20},150,[24],"This study aims to evaluate the efficacy and safety of lesigercept in approximately 150 participants with CSU. By enrolling participants with an inadequate response to H1-antihistamines, including those previously treated with omalizumab, this study is expected to provide evidence for the clinical utility of lesigercept and to further characterize its benefit-risk profile in the target participant population.",[146,147],"Allergic Diseases","Chronic Spontaneous Urticaria (CSU)",[149,150,151,152,153,154,155,156],"CSU","YH35324","Allergic disease","Chronic Spontaneous Urticaria","Yuhan","GI-301","Lesigercept","M9010","2026-04-12",{"date":159,"type":45},"2026-04-15",{"date":161,"type":45},"2026-03-26",{"date":163,"type":20},"2027-07-24",{"name":51,"class":52},30,{"id":167,"slug":168,"hasResults":11,"nctId":169,"briefTitle":170,"officialTitle":171,"acronym":4,"eligibilityCriteria":172,"healthyVolunteers":89,"sex":173,"minAge":90,"maxAge":174,"enrollmentInfo":175,"targetDuration":4,"studyType":21,"phases":177,"briefSummary":178,"conditions":179,"keywords":181,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":184,"lastUpdatePostDateStruct":185,"startDateStruct":187,"completionDateStruct":189,"leadSponsor":191,"locationsCount":106},"100555886","phase-1-a-first-in-human-single--and-multiple-ascending-dose-study-of-yh35995-in-healthy-adult-male-participants-100555886","NCT06517914","A First-in-Human, Single- and Multiple-Ascending Dose Study of YH35995 in Healthy Adult Male Participants","A First-in-Human, Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single- and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Following Oral Administration of YH35995 in Healthy Adult Male Participants","Inclusion Criteria:\n\n* Male between the ages of 19 and 45 at the time of providing written consent\n* Participants who weigh at least 50 kg at screening and have a body mass index (BMI) of at least 18.0 kg\u002Fm2 and less than 30 kg\u002Fm2\n* Participants who have been fully informed about and fully understand this study, have voluntarily decided to participate, and have agreed in writing to comply with the guidelines of the study during the duration of the study\n\nExclusion Criteria:\n\n* Participation in a bioequivalence trial or any other clinical trials within 6 months prior to the first scheduled dose of the IP (within 1 month of the first scheduled dose for participants who have taken part in a dietary supplement clinical trial)\n* Individuals with clinically significant abnormal results that do not match any other inclusion\u002Fexclusion criteria, as determined by the principal investigator and the delegated persons(investigator)\n* Individuals who are unwilling or unable to comply with the participant guidelines described in this protocol","MALE","45 Years",{"count":176,"type":20},86,[23],"This is a randomized, double-blind, first-in-human study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple oral doses of YH35995",[180],"Healthy Participants",[182,183],"YH35995","Gaucher Disease","2025-11-17",{"date":186,"type":45},"2025-11-21",{"date":188,"type":45},"2024-07-29",{"date":190,"type":20},"2027-06",{"name":51,"class":52},{"id":193,"slug":194,"hasResults":11,"nctId":195,"briefTitle":196,"officialTitle":197,"acronym":4,"eligibilityCriteria":198,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":199,"targetDuration":4,"studyType":21,"phases":201,"briefSummary":202,"conditions":203,"keywords":206,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":208,"lastUpdatePostDateStruct":209,"startDateStruct":211,"completionDateStruct":213,"leadSponsor":215,"locationsCount":216},"100563484","phase-1-a-phase-12-open-label-multicenter-fih-study-to-evaluate-safety-tolerability-pk-and-anti-tumor-activity-of-yh42946-100563484","NCT06616766","A Phase 1\u002F2, Open-label, Multicenter, FIH Study to Evaluate Safety, Tolerability, PK and Anti-tumor Activity of YH42946","A Phase 1\u002F2, Open-label, Multicenter, FIH Study to Evaluate the Safety, Tolerability, PK and Anti-tumor Activity of YH42946 in Patients With Locally Advanced or Metastatic Solid Tumors With HER2 Aberration and EGFR Exon 20 Insertion","Inclusion Criteria:\n\n* ECOG performance status 0 or 1\n* Estimated life expectancy of at least 3 months\n* Patients who have progressed on or after all available standard therapies or for whom standard treatment is inappropriate\n* Mandatory provision of archived or fresh tumor tissue in quantity sufficient to allow for retrospective confirmation of HER2 or EGFR mutation\n* A patient with a history of brain metastases must have had all lesions treated\n* Adequate organ function defined as all of the following:\n\n  * Adequate bone marrow function (within 1 week prior to first administration): Neutrophils≥1.5 x10\\*9 cells\u002FL (Criteria must be met without the use of Granulocyte-Colony Stimulating Factor (G-CSF) within last week prior to testing.); platelet count≥75 x10\\*9 cells\u002FL; Hb ≥9g\u002FdL (Criteria must be met without packed red blood cell (pRBC) transfusion within last week prior to testing.)\n  * Adequate hepatic function: Serum bilirubin≤1.5 x upper limit of normal (ULN), and serum transaminase (either aspartate transaminase (AST) or alanine transaminase (ALT)) ≤ 3 x ULN if no demonstrable liver metastases, or otherwise ≤ 5 x ULN if transaminase elevation is attributable to liver metastases (within 1 week prior to first administration)\n  * Adequate renal function: Serum creatinine ≤ 1.5 x ULN or Estimated glomerular filtration rate (eGFR) \\> 60 mL\u002Fmin per 1.73 m\\*2 according to the site's calculation method.\n\n\\[Dose Escalation part only\\]\n\n* Histologically or cytologically confirmed diagnosis of advanced, and\u002For metastatic non-hematologic malignancy\n* Documented HER2 or EGFR mutation (HER2 mutation or EGFR exon 20 insertion, HER2 amplification or overexpression)\n\n\\[Dose Expansion part only\\]\n\n* Patients with histologically or cytologically confirmed locally advanced or metastatic NSCLC HER2 exon 20 insertion (Cohort 1)\n\nExclusion Criteria:\n\n* Patient with symptomatic or progressive brain metastases\n* Known or suspected leptomeningeal disease (LMD)\n* Uncontrolled spinal cord compression\n* History of acute coronary syndromes, including myocardial infarction, coronary artery bypass graft, unstable angina, coronary angioplasty or stenting within past 24 weeks\n* History of or current Class II, III or IV heart failure as defined by the New York Heart Association (NYHA) functional classification system\n* Medical, psychiatric, cognitive or other conditions that compromise the patients ability to understand the patient information, to give informed consent, to comply with the study protocol or to complete the study\n* Any severe concurrent disease or condition (includes active infections, cardiac arrhythmia) that in the judgment of the Investigator would make study participation inappropriate for the patient\n* History of (non-infectious) interstitial lung disease (ILD) or pneumonitis that required steroids, or any evidence of current ILD or pneumonitis\n* History of a second primary cancer with the exception of\n\n  1. curatively treated non-melanomatous skin cancer,\n  2. curatively treated cervical or breast carcinoma in situ, or\n  3. other malignancy with no known active disease present and no treatment administered during the last 2 years\n* Infection with human immunodeficiency virus (HIV) or prior hepatitis B or active chronic hepatitis B or active hepatitis C\n* Major surgery within 4 weeks prior to the first dose of study treatment",{"count":200,"type":20},161,[23,24],"The goal of this YH42946-101 is to evaluate the safety, Tolerability, Pharmacokinetics and anti-tumor activity of YH42946 in patients with locally advanced of metastatic solid tumors with HER2 aberration and EGFR exon 20 insertions.",[204,205],"NSCLC (Non-small Cell Lung Cancer)","Solid Tumor",[207],"YH42946-101","2025-11-02",{"date":210,"type":45},"2025-11-04",{"date":212,"type":45},"2024-10-02",{"date":214,"type":20},"2028-07-29",{"name":51,"class":52},8,{"id":218,"slug":219,"hasResults":11,"nctId":220,"briefTitle":221,"officialTitle":222,"acronym":4,"eligibilityCriteria":223,"healthyVolunteers":11,"sex":16,"minAge":90,"maxAge":4,"enrollmentInfo":224,"targetDuration":4,"studyType":21,"phases":225,"briefSummary":227,"conditions":228,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":230,"lastUpdatePostDateStruct":231,"startDateStruct":233,"completionDateStruct":235,"leadSponsor":237,"locationsCount":238},"100564190","phase-3-clinical-trial-to-evaluate-the-safety-and-efficacy-of-ntcb02-1-in-patients-who-require-parenteral-nutrition-100564190","NCT06625957","Clinical Trial to Evaluate the Safety and Efficacy of NTCB02-1 in Patients Who Require Parenteral Nutrition","A Randomized, Open-labeled, Multi-center, Active-controlled, Parallel-group Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of NTCB02-1 Versus NTCB-C in Patients Who Require Parenteral Nutrition","Inclusion Criteria:\n\n* Those who are 19 years old or older at the screening visit\n* Patients are expected to require PN for more than 3 days\n* Patients who voluntarily signed the consent form\n\nExclusion Criteria:\n\n* Patients are expected difficult to survive more than 3 days\n* Patients BMI is over 30 kg\u002Fm2\n* Patients having hypersensitivity to any peanut-, fish-, soy-, egg protein, or investigational drug\n* Patients with difficult central venous line\n* Patients judged to be unsuitable for this trial by investigators",{"count":93,"type":20},[226],"PHASE3","A Randomized, Open-labeled, Multi-center, Active-controlled, Parallel-group Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of NTCB02-1 versus NTCB-C in patients who require parenteral nutrition",[229],"Parenteral Nutrition","2025-01-05",{"date":232,"type":45},"2025-01-07",{"date":234,"type":45},"2024-12-04",{"date":236,"type":20},"2025-07-18",{"name":51,"class":52},5,{"id":240,"slug":241,"hasResults":11,"nctId":242,"briefTitle":243,"officialTitle":244,"acronym":4,"eligibilityCriteria":245,"healthyVolunteers":11,"sex":16,"minAge":90,"maxAge":246,"enrollmentInfo":247,"targetDuration":4,"studyType":249,"phases":4,"briefSummary":250,"conditions":251,"keywords":254,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":256,"lastUpdatePostDateStruct":257,"startDateStruct":259,"completionDateStruct":261,"leadSponsor":263,"locationsCount":106},"100503458","an-observational-prospective-study-to-assess-the-efficacy-and-safety-of-adalloce-in-patients-with-ra-and-as-100503458","NCT05835518","An Observational, Prospective Study to Assess the Efficacy and Safety of Adalloce in Patients With RA and AS","An Observational, Prospective Study to Assess the Efficacy and Safety of Adalloce in Patients With Rheumatoid Arthritis and Ankylosing Spondylitis","Inclusion Criteria:\n\n1. Men and women between the ages of over 19 and under 75 at the time of consent\n2. Patients diagnosed with RA or AS at least 3 months prior to the study registration\n3. Patients who are scheduled to be prescribed Adalloce according to the doctor's opinions\n4. Patients who have never received Adalloce\n5. Patients who voluntarily gave their written consent after being sufficiently explained about the purpose and contents of this study\n\nExclusion Criteria:\n\n1. Patients with hypersensitivity to this drug or its components\n2. Patients with active tuberculosis or other severe infection such as sepsis or opportunistic infection\n3. Patients with moderate to severe heart failure (NYHA class III\u002FIV)\n4. Patients who are judged to be inappropriate for Adalloce administration according to the approved conditions\n5. Patients who are not suitable for participation in this study according to the judgment of the investigator\n6. Patients participating in other drug clinical trials (Adalloce PMS participants cannot participate in this study)","74 Years",{"count":248,"type":20},1000,"OBSERVATIONAL","This Study is to Assess the Efficacy and Safety of Adalloce in Patients With Rheumatoid Arthritis and Ankylosing Spondylitis, An Observational, Prospective Study",[252,253],"Rheumatoid Arthritis","Ankylosing Spondylitis",[255],"The Efficacy and Safety of Adalloce","2023-05-08",{"date":258,"type":45},"2023-05-09",{"date":260,"type":45},"2023-01-26",{"date":262,"type":20},"2026-08",{"name":51,"class":52},""]